Potency equivalency factors for some polycyclic aromatic hydrocarbons and polycyclic aromatic hydrocarbon derivatives
Potency equivalency factors for some polycyclic aromatic hydrocarbons and polycyclic aromatic hydrocarbon derivatives
复制标题
DOI：
10.1006/rtph.1998.1235
复制
发表时间：
1998-08-01
影响因子：
3.4
通讯作者：
Salmon, AG
中科院分区：
文献类型：
--
作者：
Collins, JF;Brown, JP;Salmon, AG
基于数据偏好方案，针对 21 种多环芳烃 (PAH) 和 PAH 衍生物得出了相对于苯并[a]芘的致癌效力等效因子 (PEF)。 PEF 仅适用于在生物测定中已证明具有致癌性的 PAH。根据针对加州 65 号提案进行的快速风险评估，提出了四种其他致癌 PAH 的癌症效力值和吸入单位风险。大量 PAH 和 PAH 衍生物被认为具有致突变性或遗传毒性，并且可能具有有限的致癌性证据，但本次评估中未考虑这些化合物。新的癌症生物测定数据和可能的结构活性分析可能表明额外的多环芳烃具有致癌性。因此，当获得此类数据时，其他多环芳烃可能被确定为潜在的人类致癌物。然而，在此之前，建议用于风险评估的 PEF 仅针对目前归类为致癌物的 PAH 进行了估计。
Potency equivalency factors (PEFs) for cancer induction relative to benzo[a]pyrene have been derived for 21 polycyclic aromatic hydrocarbons (PAHs) and PAH derivatives based on a data preference scheme. PEFs have been derived only for PAHs with demonstrated carcinogenicity in bioassays. Cancer potency values and inhalation unit risks are presented for four additional carcinogenic PAHs based on expedited risk assessments conducted for California's Proposition 65. A much larger number of PAHs and PAH derivatives are considered mutagenic or genotoxic and may have limited evidence for carcinogenicity, but these compounds are not considered in this evaluation. New cancer bioassay data and possibly structure-activity analysis may indicate that additional PAHs are carcinogenic. Thus, additional PAHs may be identified as potential human carcinogens when such data become available. However, until that time the PEFs proposed for use in risk assessment were estimated only for PAHs currently classified as carcinogens.